Anixa Adds An Ovarian Cancer Vaccine To Their Portfolio

Dr. Amit Kumar and Anixa Biosciences have added another potential jewel to their crown. With the licensing of a promising ovarian cancer vaccine from...

Anixa Biosciences Announces Licensing Agreement with Cleveland Clinic for Ovarian Cancer Vaccine Technology

Tailwinds' Take: this expansion of Anixa's relationship with The Cleveland Clinic demonstrates the value of their partnership. Dr. Tuohy's group is a leader in...

Timing Is Everything…Or Is It?

The market's rally, especially in small-cap, continued this past week and Tailwinds' stocks participated along with the broader indexes. In particular, performance of our...

Anixa Biosciences and Cleveland Clinic File IND Application for Breast Cancer Vaccine

Tailwinds' Take: Yay! This long-awaited IND filing is game-changing for Anixa as it marks a significant milestone and brings them to the verge of...

The Biden Rally

As most of my readers know, I reserve Saturday mornings for writing my weekly newsletter. This week, however, Saturday morning marks the arrival of...

Sell Mortimer, Sell!!!

What do I want to say? That's the question that comes into my head every Saturday morning. This newsletter is an opportunity. An opportunity...

Anixa Biosciences to Host Conference Call to Provide Update on Programs

Tailwinds' Take: expecting to hear that an IND was filed for their breast cancer vaccine. Should be very positive. SAN JOSE, Calif., Oct. 27, 2020...

Post Traumatic Investment Disease Redux? Nah, Just A Dose Of Reality

Having survived the rocky cliffs of Moab, I think I jinxed myself with last week's cover photo asking "What could go wrong?" Turns out...

This Week In Moab

Having written a newsletter for almost 200 consecutive weeks, I didn't want to miss this week. But, I am mountain biking in Moab Utah,...

The Final Push…

Like the debate, 2020 has been a sh**-show. Pandemics, political divisiveness, fires...it's not been a beach party to say the least. Yet, here we stand...

Anixa’s Breast Cancer Vaccine; A Conversation With Dr. Vince Tuohy

This week I had the opportunity to speak with Dr. Vincent Tuohy of the Cleveland Clinic. Dr. Tuohy is the inventor and research leader...

West Bound and Down

After fortuitously sheltering in place on the east coast for seven weeks, we are heading back for CA this week. We seem to have,...

Under The Radar…Key Data-Points From The Last Week That Nobody Really Noticed

The easiest way to make money in the market is trading off of insider information. It is also highly illegal, will put you in...

Is It Finally Time For Anixa to Shine?

A little more than a year and a half ago, I declared that Anixa (ANIX) was my stock of the year for 2019. They...

Goodbye August (almost)…

Okay, I know it's not the official end of August...that takes place on Monday. However, due to the fact that the month is basically...

This Week at Tailwinds

Stocks continued to climb the proverbial wall of worry last week, with the S&P briefly managing to touch an all-time high and the Russell...

Anixa and OntoChem Announce Identification of Additional Covid-19 Compounds

Tailwinds' Take: this program is still in its early stages, but has great potential. We continue to monitor this progress while we get closer...

OnTrak For A Great Year

Telehealth was the all the rage this past week. First The Centers for Medicare & Medicaid Services (CMS) is proposing changes to expand telehealth...

Anixa Biosciences Breast Cancer Vaccine Technology Nearing FDA Submission

Tailwinds' Take: exciting news for ANIX as they hope to have the IND filed by the end of Q3. The product has shown incredible...

Random Thoughts on a Number of Stocks…

There's certainly a lot going on in the world at large right now and none of it seems too good. Covid-19 refuses to go...

Previewing the 2nd Half of 2020…and Other Updates From The Week

Greetings from...wait for it...Ashland Oregon. Yes, it was so good, we came back for more. The weather here is great, the riding is outstanding...

Anixa Biosciences’ CAR-T Cancer Therapy Receives Intention to Grant Notice from the European Patent...

Tailwinds' Take: in my humble opinion, the CAR-T program at ANIX is the most exciting asset the Company with an IND filing expected in...

Anixa and OntoChem Announce Completion of Initial Screening Program and Identification of Additional Covid-19...

Tailwinds' Take: this program has a high potential reward with very minimal financial risk for Anixa. Early progress is great, but more exciting will...

Happy 4th of July…A Review of June and Other Notes

With June closing out, we can now reflect on what was the best quarter the stock market has seen since the turn of the...

Anixa Announces Strategic Program Realignment Focused on Advancement of its Therapeutic and Vaccine Pipeline

Tailwinds' Take: we view this as a net positive. With CV-19 distracting all potential diagnostic partners, best to focus efforts on therapeutics where the...

Summer is Coming

When you receive this newsletter, it will be June 21st, the official start of summer. Typically for stocks you have a summer doldrums, "sell...

This Week at Tailwinds…Scratching My Head

Perhaps it's because I've not seen the barber during the pandemic, but the market has me left me scratching my head. Some recent stock...

Anixa Biosciences and OntoChem Have Synthesized Four Potential Covid-19 Drugs for Testing in Biological...

Tailwinds' Take: great first steps. Moving successfully through biological assays and into animal testing is the big value driver. Hopefully we start hearing some...

June Preview…Plus Much More!

May was another strong month for the market as the stimulus package and expectations for a strong re-opening of the economy kept the rebound...

This Week’s Recap: Skinny Trails, Anixa Looks Primed, Atomera Launching

As most readers know by now, I love mountain biking. It's great exercise and there's a tremendous thrill to hitting a difficult stretch of...

Bada Bing Bada Boom

As if on cue, the market took a turn lower last week. This will be but a quick note on the market, as I'm...

The Week In Review

The market continues to ignore my bearish calls and, instead, keeps chugging higher. I'm at a loss to explain this, as are most professional...

Anixa Biosciences and OntoChem Announce Discovery of First Covid-19 Therapeutic Candidate

Tailwinds' Take: this selection of a therapeutic candidate has happened very quickly and demonstrates the powerful potential of Dr. Kumar's teams' A.I. expertise combined...

The Eye Of The Storm…This Week In Tailwinds’ World

Well, I've been expecting it and it appears that it's here. The market put up one of its best months ever in April, but...

Anixa and INmune: Unique COVID-19 Opportunities In Tailwinds’ Universe

CoronaVirus is not only the buzzword for the whole market both on the negative side as business falls off a cliff, and positively as...

This Week in Stocks

While the markets may not have had the most volatile week of the year, nor come close, it was a very topsy-turvy five days...

Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Biomarker Insights Highlighting Cchek™ Liquid...

Tailwinds' Take: being able to distinguish men who are disease free could dramatically reduce the number of unnecessary biopsies performed annually, resulting in both...

Anixa Biosciences and OntoChem Announce Collaboration to Develop Novel COVID-19 Therapeutics

Tailwinds' Take: this is very interesting news. We have long stated our respect for Dr. Kumar. His ability to think outside the box is...

IF Alpha?

My biggest concern last fall was, "what if Bernie gets into office?" This fear was driven partially by the fact that the market would...

Take a Deep Breath…Updates on the Market and Several Stocks

My Take on The Market This was a good week in the market, which was a welcome relief. We had a big bailout announced by...

It’s Definitely a Beer Market

Sometimes a typo can hit the sweet spot, right? When I got the text that we're entering a beer market...well, let's just say that...

Anixa: an Update on Their Breast Cancer Vaccine Program

Vaccines seem to be all the rage these days. Well, at least ones related to the CoronaVirus. If you are somehow associated with the...

Anixa Biosciences Announces Presentation at AI and Big Data in Cancer Conference

SAN JOSE, Calif., March 2, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the...

Thoughts From The Last Week…

Lots going on in Tailwinds' universe recently. Here I recap conversations and observations from the prior week's trading... This screen shot says it all...if Druck...

Anixa Biosciences and Moffitt Cancer Center Announce Completion of Viral Vector Reformulation for CAR-T...

Tailwinds' Take: this is very good news for Anixa as they remain on track for their IND filing. With the reformulation, ANIX is in...

Artificial Intelligence and the Oscars

It's Oscar week right now and times they are a-changing. Netflix is up for numerous awards as they try to bludgeon their way into...

Slogging Through Winter

I was skiing outside Seattle last weekend. Steven's Pass ski resort, to be precise. They have gotten a lot of snow up there this...

Early Returns

New Years always brings out the prognosticator in all of us. Everyone likes to predict what the market will do, what sectors will shine...

Anixa Biosciences Announces Presentation at AACR Liquid Biopsies Conference

SAN JOSE, Calif., Jan. 6, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the...

Visions of 2020

This last week was actually a very good week for the Tailwinds' portfolio. Despite the overall quiet of a holiday week (or maybe because...

Anixa Biosciences to Present at Biotech Showcase 2020

SAN JOSE, Calif., Dec. 23, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the...

Anixa: Transcript of Investor Update Conference Call

Please click on the link below to see the complete transcript from Anixa's Investor Update conference call of December 17th, 2019. ANIXA_12172019 transcript

Anixa Biosciences Announces Commercial Launch of Cchek™ Prostate Cancer Confirmatory Test

Tailwinds' Take: very positive news as Anixa has Anixa launches what could be, over time, a very disruptive diagnostic test. Tomorrow will see the...

LD Micro Recap and Other Thoughts From Last Week

LA is usually a great place to be in December, compared to the rest of the nation. With the weather being generally sunny and...

Anixa Biosciences to Host Conference Call to Discuss Plans for 2020

SAN JOSE, Calif., Dec. 13, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight...

Anixa Delays CAR-T to Improve Chances of Success

This morning Anixa (ANIX) announced the delay of their intended IND filing for a novel CAR-T therapy targeting ovarian cancer. This delay is likely...

Anixa Biosciences Provides Update on CAR-T Program

Tailwinds' Take: in my conversations with Dr. Kumar, I got the sense that the clinical team thought the product was ready to go into...

Several Thoughts On Micro-Cap Stocks I Follow

The market seems took a little hit this week, then bounced back. The net result of which was the wind coming out of the...

Anixa Biosciences Announces Genesis Research to Join Cchek™ Prostate Cancer Study

Tailwinds' Take: there is some momentum building behind Cchek as partners are signing on rapidly. Once it's approved, groups like this will turn into...

Anixa Biosciences Announces Collaboration with Urology Centers of Alabama on Cchek™ Prostate Cancer Study

SAN JOSE, Calif., Nov. 22, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the...

Anixa Biosciences Announces Collaboration with Idaho Urologic Institute on Cchek™ Prostate Cancer Study

Tailwinds' Take: key sentence here is from Dr. Kumar's quote, "commercial launch later this year." SAN JOSE, Calif., Nov. 20, 2019 /PRNewswire/ -- Anixa Biosciences, Inc....

Show Me The Money

As the stock market hits new highs on all the major indexes seemingly daily, it appears that the market has moved to a “risk...

Anixa Biosciences Announces Patent Issued for its Breast Cancer Vaccine

Tailwinds' Take: with ANIX ready to file an IND within weeks, this patent helps secure their IP around a very promising potential cure for...

Tailwinds’ Take: Novartis Executive Dr. Emanuele Ostuni Added to Anixa’s Scientific Advisory Board

Tailwinds’ Take: Dr. Ostuni joining the Scientific Advisory Board (SAB) of Anixa could have major significance to the Company. Investors should really start paying...

Anixa Biosciences Announces Collaboration with Urology San Antonio on Cchek™ Prostate Cancer Study

Tailwinds' Take: the gating factor for Cchek obtaining CLIA approval is recording a sufficient quantity of samples. The data continues to be even better...

Anixa Biosciences Announces Abstract Accepted for Presentation at the 34th Annual Meeting of the...

Tailwinds' Take: With CLIA approval for Cchek in prostate cancer expected within weeks, Anixa is already moving forward on a second indication. The recent...

Anixa Biosciences Appoints Dr. Thomas Schlumpberger as Executive Vice President of Diagnostics to Head...

Tailwinds' Take: hiring an executive to lead business development is key for Cchek as Anixa will be looking to move the product onwards towards...

Anixa Biosciences Names Cancer Vaccine Pioneer Dr. Ian H. Frazer to Scientific Advisory Board

Tailwinds' Take: the key takeaway from this is that the top scientists in the world are now coming on board to work with Anixa....

Volatility Creating Opportunity…

I tend to be very much a buy and hold investor. I take positions, add to them as I gain confidence and generally let...

Anixa Biosciences Commences Collaboration with Potomac Urology Center on Cchek™ Prostate Cancer Study

Tailwinds' Take: endorsement from KOL's like the Potomac Urology Center is key to getting Cchek broad acceptance and a maximum valuation when they eventually...

An Interview With Anixa’s Dr. Amit Kumar

Now that the summer is over, and the fall conference season is ahead I thought it might be a good time for an interview...

Anixa Biosciences Congratulates Scientific Advisory Board Member Dr. H. Michael Shepard as a 2019...

Tailwinds' Take: The Lasker Award is a big honor and demonstrates the strength of Anixa's scientific board. Dr. Shepard's work in breast cancer has...

Fall Investor Preview Along With A Belated August Recap

I’ve held off on my August recap much like a war veteran will refrain from telling tales from the trenches. Not that my experiences...

LD Micro Recap

Today was the LD Micro SF Summit. As Chris Lahiji said, 27 companies, 27 investors. We all sit around the table and they bring...

If I Had A Nickel For Every Buying Opportunity…

The path to being a good investor is to be able to see what the future holds and place your bets accordingly. If you...

Anixa Biosciences Announces VA North Texas Health Care System to Join Cchek™ Prostate Cancer...

Tailwinds' Take: this is the third VA hospital to join the Cchek study. This demonstrates the success the diagnostic must be showing in other...

Anixa Biosciences Announces Additional Patent Issued on Cancer Detection Technology

SAN JOSE, Calif., July 24, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight...

Anixa Biosciences Announces U.S. Department of Veterans Affairs VA Maryland Health Care System Joins...

SAN JOSE, Calif., July 22, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer,...

Anixa Update Call Full Transript

Operator:Good day, everyone. Welcome to today’s corporate update and discussion of recent alliance with Cleveland Clinic on breast cancer vaccine. At this time, all...

Anixa Licenses Another Potential Blockbuster

In January we proclaimed Anixa to be Tailwinds’ stock of the year. This designation was awarded due to potential major milestones in the both...

Anixa Biosciences Announces a Strategic Alliance and Licensing Agreement with Cleveland Clinic for an...

SAN JOSE, Calif., July 17, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that...

Anixa Biosciences Highlights Recent Publication in The Journal of Experimental Medicine on Myeloid Derived...

Tailwinds' Take: This is a very technical study, but here are key points: 1. George Dominguez and Amit Kumar from Anixa are co-authors with the scientists at...

A Shallow Dive From The Deep South

In what is shaping up as a never-ending quest to provide newsletter coverage from anyplace not named "home", this week's letter comes from Raleigh,...

Three Thoughts on Anixa’s S-3

This afternoon Anixa (ANIX) filed a mixed-shelf offering of up to $100M in securities. Included in this was a sales agreement with B. Riley...

Markets Trade Down In May…June Preview

I'm not sure why, but it seems that every time I feel the Tailwinds' Portfolio is poised for big gains, the market enters a...

A Brief Update on Anixa

Yesterday I had the opportunity to sit down with Anixa’s Dr. Amit Kumar, CEO, and Michael Catelani, CFO. Our discussion was rather wide ranging...

Anixa Biosciences to Present at the CYTO 2019 – 34th Congress of the ...

Tailwinds' Take: additional data from the ongoing ResearchDx partnership, which is intended to certify Cchek as a CLIA approved diagnostic, will be presented. Anixa...

B Riley, Day Two Recap

Day two of B Riley was a slightly abbreviated day for yours truly as I had a flight to catch. I did manage to...

Anixa Biosciences Announces Completion of Cchek™ Analytical Verification at CLIA Laboratory

Tallwinds' Take: this important milestone has been achieved within the expected development timeline and Cchek is on track for a Q3 launch. With more...

Bernie Shakes Up Biotech; Anixa Insider Takes Advantage

As the pre-election momentum builds around "MediCare For All", healthcare stocks have become quite jittery. Drug stocks, and in particular the biotech companies, have...

US Patent & Trademark Office Issues Patent on Anixa Biosciences CAR-T Cancer Treatment Technology

Tailwinds' Take: this is a very positive step for Anixa as it insures that they have rights to this treatment as a platform for...

Anixa Biosciences Extends and Expands its Collaboration with New Jersey Urology

Tailwinds' Take: I believe investors don't quite get the lack of support for the PSA in the medical community. Cchek, if and when approved,...

Anixa Biosciences Presents Cchek™ Prostate Cancer Detection Data at AACR Annual Meeting

SAN JOSE, Calif., April 3, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to...

Anixa’s CEO to Present at Major Cancer Symposium

On May 15th, Dr. Amit Kumar will be on a panel discussing cancer therapies for solid tumors. This panel is at a conference hosted...

U.S. Department of Veterans Affairs and McGuire Research Institute Join Anixa Biosciences Cchek™ Prostate...

Tailwinds' Take: two keys to this press release. First, this should provide a steady stream of samples, keeping the timeline intact for developing the...

Anixa Biosciences to Present Cchek™ Technology and Data at the Molecular Medicine Tri-Conference

Tailwinds' Take: another oral presentation, at a key conference no less, is going to help Cchek gain recognition right before its launch. Interestingly, data...

Anixa Biosciences to Present Latest Prostate Cancer Data at the 2019 American Association for...

Tailwinds' Take: this is positive for a couple reasons. Oral presentations are not handed out willy-nilly...it shows that the medical community is catching on...

Anixa Partners With ResearchDX…Tailwinds’ Take

This morning, Anixa announced that they have achieved one of their key milestones for 2019, namely that of partnering with an independent clinical laboratory...

Anixa Biosciences Announces Partnership with ResearchDx for Launch of Cchek™ Prostate Cancer Confirmation Test

Tailwinds' Take: Anixa is executing to their plan. Having a diagnostic in the market by Q3 should be eye-opening for institutional investors who have...

Anixa Biosciences Extends Collaborative Research Agreement with The Wistar Institute and Leading Myeloid-derived Suppressor...

Tailwinds' Take: working with the leader in MDSC research has enabled the progress of their Cchek diagnostic and will likely lead to more potential...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.